$8.18
3.31% day before yesterday
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US75943R1023
Symbol
RLAY

Relay Therapeutics Inc Stock price

$8.18
+0.69 9.21% 1M
+4.58 127.22% 6M
-0.28 3.31% YTD
+3.88 90.23% 1Y
-6.76 45.25% 3Y
-32.26 79.77% 5Y
-26.87 76.66% 10Y
-26.87 76.66% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.28 3.31%
ISIN
US75943R1023
Symbol
RLAY
Industry

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$821.4m
Net debt
positive
Cash
$596.4m
Shares outstanding
172.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
169.6 | 117.6
EV/Sales
98.3 | 68.1
EV/FCF
negative
P/B
2.3
Financial Health
Equity Ratio
89.3%
Return on Equity
-43.4%
ROCE
-51.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$8.4m | $12.1m
EBITDA
$-322.8m | $-324.4m
EBIT
$-327.1m | $-325.4m
Net Income
$-297.6m | $-305.0m
Free Cash Flow
$-248.9m
Growth (TTM | estimate)
Revenue
-76.5% | 20.4%
EBITDA
50.7% | 11.6%
EBIT
50.5% | 12.6%
Net Income
50.7% | 9.7%
Free Cash Flow
11.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,863.0% | -2,691.2%
EBIT
-3,914.4%
Net
-3,561.4% | -2,530.1%
Free Cash Flow
-2,978.3%
More
EPS
$-1.7
FCF per Share
$-1.4
Short interest
14.2%
Employees
197
Rev per Employee
$50.0k
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
8.36 8.36
76% 76%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
54% 54%
734%
- Research and Development Expense 283 283
51% 51%
3,391%
-323 -323
51% 51%
-3,861%
- Depreciation and Amortization 4.29 4.29
22% 22%
51%
EBIT (Operating Income) EBIT -327 -327
50% 50%
-3,913%
Net Profit -298 -298
51% 51%
-3,560%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
GlobeNewsWire
22 days ago
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongo...
Negative
The Motley Fool
about one month ago
Chief Corporate Development Officer Peter Rahmer sold more than 40,000 shares of Relay Therapeutics in October. The sale, worth about $300,000, was partially due to company policy regarding vested restricted stock units.
Positive
The Motley Fool
about one month ago
New York City-based Commodore Capital increased its RLAY position by 3,650,000 shares in the third quarter. The transaction value represented 0.7% of Commodore's 13F AUM for the period.
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 197
Founded 2015
Website relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today